Levodopa

Levodopa. It is the metabolic precursor to the neurotransmitters dopamine, norepinephrine, and epinephrine, and is the most effective symptomatic treatment for Parkinson's disease. Administered orally, it crosses the blood–brain barrier and is converted into dopamine within the basal ganglia, helping to restore depleted dopamine levels. Its use is often combined with a peripheral decarboxylase inhibitor like carbidopa to prevent its breakdown outside the central nervous system and reduce side effects.

Medical uses

The primary indication is the management of motor symptoms in Parkinson's disease, including bradykinesia, rigidity, and tremor. It is also used in the treatment of dopamine-responsive dystonia and may be part of the management strategy for restless legs syndrome. Clinical efficacy is typically sustained for several years, though its long-term use is associated with motor complications. It is often initiated when symptoms begin to impair daily function, as determined by assessments like the Unified Parkinson's Disease Rating Scale.

Adverse effects

Common peripheral side effects include nausea, orthostatic hypotension, and cardiac arrhythmia, which are often mitigated by co-administration with carbidopa. Long-term central nervous system effects are more problematic, including motor fluctuations such as the "wearing-off" phenomenon and dyskinesia. Psychiatric adverse effects can include visual hallucinations, confusion, and impulse control disorders. The on-off phenomenon represents a severe fluctuation in motor control.

Pharmacology

As a prodrug, it is actively transported across the blood–brain barrier via the large neutral amino acid transporter. Once in the brain, it is decarboxylated to dopamine by the enzyme aromatic L-amino acid decarboxylase, primarily within the striatum. Its pharmacokinetics are complex; absorption competes with dietary amino acids and can be impaired by gastroparesis. The plasma half-life is short, approximately 1-2 hours, necessitating frequent dosing or use of extended-release formulations.

History

The compound was first isolated from the seeds of the Mucuna pruriens plant in 1910-1913. Its significance in neurology was established through the pioneering work of Arvid Carlsson, who demonstrated its role in dopamine synthesis and its behavioral effects, for which he later received the Nobel Prize in Physiology or Medicine. The landmark clinical studies by George Cotzias in the 1960s proved its dramatic efficacy in Parkinson's disease, revolutionizing treatment. The development of the carbidopa combination therapy by Merck & Co. significantly improved its therapeutic index.

Society and culture

The drug's dramatic effects were famously depicted in Oliver Sacks's book *Awakenings*, later adapted into a film starring Robert De Niro. It is on the World Health Organization's List of Essential Medicines. Generic versions are widely available, though newer formulations like carbidopa/levodopa/entacapone and intestinal gel infusion systems have been developed by companies like AbbVie. Its discovery fundamentally altered the prognosis of Parkinson's disease and remains a cornerstone of therapy, symbolizing one of the great successes of neuropharmacology.

Category:Dopaminergics Category:World Health Organization essential medicines Category:Parkinson's disease